Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,924 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Kim SJ, Cheong JW, Kim DY, Lee JH, Lee KH, Kim YK, Kim HJ, Song IC, Jo DY, Lee JO, Bang SM, Park J, Lee JH, Lee WS, Joo YD, Maeng CH, Yoon HJ, Lee NR, Kwak JY, Kim KH, Won JH, Han BR, Zang DY, Moon JH, Sohn SK, Bae SH, Ryoo HM, Kim SY, Lee MH, Min YH; Korean Society of Hematology AML/MDS Working Party. Kim SJ, et al. Among authors: kim yk, kim hj, kim dy, kim sy, kim kh. Int J Hematol. 2014 Aug;100(2):141-51. doi: 10.1007/s12185-014-1617-8. Epub 2014 Jul 5. Int J Hematol. 2014. PMID: 24996615
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: kim jy, kim dd, kim hj, kim yk, kim sh, kim ny. Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Ann Hematol. 2016. PMID: 26537612
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, Kim DH; L/MDS working party, Korean Society of Hematology. Kim HJ, et al. Among authors: kim h, kim yk, kim dh, kim sh, kim kh. Ann Hematol. 2013 Jan;92(2):163-71. doi: 10.1007/s00277-012-1580-5. Epub 2012 Sep 28. Ann Hematol. 2013. PMID: 23053179
The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea.
Kim JS, Cheong JW, Kim YK, Park J, Mun YC, Kang HJ, Yi HG, Lee JH, Kim YS, Ryoo HM, Kim SH, Kim HY, Kim JY, Lee DG, Kim HG, Kim H, Joo YD, Min YH. Kim JS, et al. Among authors: kim jy, kim hg, kim hy, kim h, kim yk, kim sh, kim ys. Ann Hematol. 2014 Jan;93(1):33-42. doi: 10.1007/s00277-013-1826-x. Epub 2013 Jun 27. Ann Hematol. 2014. PMID: 23807252
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome.
Ahn JS, Kim YK, Min YH, Cheong JW, Jang JH, Jung CW, Kim IH, Yoon HJ, Lee HG, Sohn SK, Moon JH, Kim H, Kim YJ, Won JH, Chung JS, Mun YC, Lee JH, Kim HJ. Ahn JS, et al. Among authors: kim ih, kim h, kim yj, kim yk, kim hj. Acta Haematol. 2015;134(1):40-8. doi: 10.1159/000368711. Epub 2015 Jun 6. Acta Haematol. 2015. PMID: 26066466 Clinical Trial.
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: kim dd, kim hj, kim yk, kim sh, kim ny. Biol Blood Marrow Transplant. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030. Epub 2015 Jul 31. Biol Blood Marrow Transplant. 2016. PMID: 26234722 Free article. Clinical Trial.
Erratum to: Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: kim jy, kim dd, kim hj, kim yk, kim sh, kim ny. Ann Hematol. 2016 Jan;95(2):363. doi: 10.1007/s00277-015-2563-0. Ann Hematol. 2016. PMID: 26630982 No abstract available.
Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ahn JS, et al. Among authors: kim dd, kim hj, kim yk, kim sh, kim ny. Ann Hematol. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z. Epub 2015 Dec 22. Ann Hematol. 2016. PMID: 26692090
5,924 results